Retrieve available abstracts of 55 articles: HTML format
Single Articles
June 2025
SACCO S, Papinutto N, Schoeps VA, Cheng S, et al High-Dose Pulse Glucocorticoid Treatment Prevents White Matter Spinal Cord
Pseudoatrophy in Newly Diagnosed Multiple Sclerosis.
Ann Neurol. 2025 Jun 24. doi: 10.1002/ana.27298. PubMedAbstract available
DISANTO G, Sacco R, Mallucci G, Zecca C, et al Effect of Cumulative Exposure to Ocrelizumab on Memory B-Cell Repopulation
Dynamics in Multiple Sclerosis.
Ann Neurol. 2025 Jun 11. doi: 10.1002/ana.27281. PubMedAbstract available
SABATINO JJ JR, Cree BAC, Hauser SL New Horizons for Multiple Sclerosis Therapy: 2025 and Beyond.
Ann Neurol. 2025 Jun 6. doi: 10.1002/ana.27270. PubMedAbstract available
April 2025
POOLE S, Sisodia N, Koshal K, Henderson K, et al Detecting New Lesions Using a Large Language Model: Applications in Real-World
Multiple Sclerosis Datasets.
Ann Neurol. 2025 Apr 25. doi: 10.1002/ana.27251. PubMedAbstract available
MURARO PA, Zito A, Signori A, Sormani MP, et al Effectiveness of Autologous Hematopoietic Stem Cell Transplantation versus
Alemtuzumab and Ocrelizumab in Relapsing Multiple Sclerosis: A Single Center
Cohort Study.
Ann Neurol. 2025 Apr 19. doi: 10.1002/ana.27247. PubMedAbstract available
PANSIERI J, Pisa M, Yee S, Gutnikova A, et al Neuropathological Evidence of Reduced Amyloid Beta and Neurofibrillary Tangles in
Multiple Sclerosis Cortex.
Ann Neurol. 2025 Apr 8. doi: 10.1002/ana.27231. PubMedAbstract available
February 2025
GUO K, Peng F, Liu J, Long Y, et al Efficacy and Safety of Ofatumumab Treatment for Anti-NMDA Receptor Autoimmune
Encephalitis (OFF-AE): A Prospective, Multicenter Cohort Study.
Ann Neurol. 2025 Feb 24. doi: 10.1002/ana.27218. PubMedAbstract available
ABBADESSA G, Nagano A, Hametner S, Howell O, et al Mapping Molecular Pathways of Multiple Sclerosis: A Gene Prioritization and
Network Analysis of White Matter Pathology Transcriptomics.
Ann Neurol. 2025 Feb 14. doi: 10.1002/ana.27216. PubMedAbstract available
HASHEMI E, Srivastava IN, Aguirre A, Yoseph ET, et al A Novel Mouse Model for Cerebral Inflammatory Demyelination in X-Linked
Adrenoleukodystrophy: Insights into Pathogenesis and Potential Therapeutic
Targets.
Ann Neurol. 2025;97:296-312. PubMedAbstract available
PAPADOPOULOS D, Magliozzi R, Bandiera S, Cimignolo I, et al Accelerated Cellular Senescence in Progressive Multiple Sclerosis: A
Histopathological Study.
Ann Neurol. 2025 Feb 1. doi: 10.1002/ana.27195. PubMedAbstract available
January 2025
MARGONI M, Storelli L, Pagani E, Preziosa P, et al Subventricular Zone Microstructure in Pediatric-Onset Multiple Sclerosis.
Ann Neurol. 2025 Jan 18. doi: 10.1002/ana.27180. PubMedAbstract available
December 2024
BRIER MR, Judge B, Ying C, Salter A, et al Increased White Matter Aerobic Glycolysis in Multiple Sclerosis.
Ann Neurol. 2024 Dec 23. doi: 10.1002/ana.27165. PubMedAbstract available
HELBIG I, Ganesan S NORSE, FIRES, and a Polygenic Trickle of Autoimmunity.
Ann Neurol. 2024 Dec 7. doi: 10.1002/ana.27148. PubMed
November 2024
BROWNLEE WJ, Vidal-Jordana A, Shatila M, Strijbis E, et al Towards a Unified Set of Diagnostic Criteria for Multiple Sclerosis.
Ann Neurol. 2024 Nov 28. doi: 10.1002/ana.27145. PubMedAbstract available
CABALLERO-AVILA M, Martin-Aguilar L, Pascual-Goni E, Michael MR, et al Long-Term Follow Up in Anti-Contactin-1 Autoimmune Nodopathy.
Ann Neurol. 2024 Nov 27. doi: 10.1002/ana.27142. PubMedAbstract available
PROTOPAPA M, Steffen F, Schraad M, Ruck T, et al Increased Disability Progression in rs10191329(AA) Carriers with Multiple
Sclerosis Is Preceded by Neurofilament Light Chain Elevations.
Ann Neurol. 2024 Nov 26. doi: 10.1002/ana.27144. PubMedAbstract available
MEUTH SG, Wolff S, Muck A, Willison A, et al Different Treatment Outcomes of Multiple Sclerosis Patients Receiving Ocrelizumab
or Ofatumumab.
Ann Neurol. 2024 Nov 25. doi: 10.1002/ana.27143. PubMedAbstract available
October 2024
WANG W, Yin J Coexistence of Acute Cerebral Infarction and Reversible Posterior Encephalopathy
Syndrome in a Patient with Hashimoto's Thyroiditis.
Ann Neurol. 2024 Oct 23. doi: 10.1002/ana.27120. PubMed
JANG Y, Hong SE, Ahn SH, Mon SY, et al Polygenic Landscape of Cryptogenic New-Onset Refractory Status Epilepticus: A
Comprehensive Whole-Genome Sequencing Study.
Ann Neurol. 2024 Oct 23. doi: 10.1002/ana.27100. PubMedAbstract available
ALZAMANAN F, Ding Y, Harroud A Obesity and Multiple Sclerosis Severity: A Mendelian Randomization Study.
Ann Neurol. 2024 Oct 21. doi: 10.1002/ana.27112. PubMedAbstract available
MESSMER ML, Salapa HE, Popescu BF, Levin MC, et al RNA Binding Protein Dysfunction Links Smoldering/Slowly Expanding Lesions to
Neurodegeneration in Multiple Sclerosis.
Ann Neurol. 2024 Oct 18. doi: 10.1002/ana.27114. PubMedAbstract available
BENKERT P, Maleska Maceski A, Schaedelin S, Oechtering J, et al Serum Glial Fibrillary Acidic Protein and Neurofilament Light Chain Levels
Reflect Different Mechanisms of Disease Progression under B-Cell Depleting
Treatment in Multiple Sclerosis.
Ann Neurol. 2024 Oct 16. doi: 10.1002/ana.27096. PubMedAbstract available
SANABRIA-DIAZ G, Cagol A, Lu PJ, Barakovic M, et al Advanced MRI Measures of Myelin and Axon Volume Identify Repair in Multiple
Sclerosis.
Ann Neurol. 2024 Oct 10. doi: 10.1002/ana.27102. PubMedAbstract available
MONTOBBIO N, Cordioli C, Signori A, Bovis F, et al Relapse-Associated and Relapse-Independent Contribution to Overall Expanded
Disability Status Scale Progression in Multiple Sclerosis Patients Diagnosed in
Different Eras.
Ann Neurol. 2024 Oct 9. doi: 10.1002/ana.27093. PubMedAbstract available
SUZUKI S, Utsugisawa K MuSK-Myasthenia Gravis and Cancer.
Ann Neurol. 2024 Oct 8. doi: 10.1002/ana.27094. PubMed
FALSO S, Iorio R Reply to "MuSK-Myasthenia Gravis and Cancer".
Ann Neurol. 2024 Oct 4. doi: 10.1002/ana.27091. PubMed
September 2024
FADDA G, Banwell B, Elliott C, Fetco D, et al Slowly Expanding Lesions Differentiate Pediatric Multiple Sclerosis from Myelin
Oligodendrocyte Glycoprotein Antibody Disease.
Ann Neurol. 2024 Sep 7. doi: 10.1002/ana.27066. PubMedAbstract available
August 2024
GRUT V, Bistrom M, Salzer J, Stridh P, et al Interactions between High Seroreactivity to Human Herpes Virus 6A and
Epstein-Barr Virus in MS Development: A Presymptomatic Case-Control Study.
Ann Neurol. 2024;96:302-305. PubMedAbstract available
July 2024
MARRODAN M, Calandri IL, Bocancea DI, Ysrraelit MC, et al Diagnostic MRI Score to Differentiate Susac Syndrome from Primary Angiitis of the
Central Nervous System and Multiple Sclerosis.
Ann Neurol. 2024 Jul 26. doi: 10.1002/ana.27043. PubMedAbstract available
SCALFARI A, Traboulsee A, Oh J, Airas L, et al Smouldering-Associated Worsening in Multiple Sclerosis: An International
Consensus Statement on Definition, Biology, Clinical Implications, and Future
Directions.
Ann Neurol. 2024 Jul 25. doi: 10.1002/ana.27034. PubMedAbstract available
FALSO S, Gessi M, Marini S, Benvenuto R, et al Cancer Frequency in MuSK Myasthenia Gravis and Histological Evidence of
Paraneoplastic Etiology.
Ann Neurol. 2024 Jul 15. doi: 10.1002/ana.27033. PubMedAbstract available
HU Y, Frisell T, Alping P, Song H, et al Hospital-Treated Infections and Risk of Disability Worsening in Multiple
Sclerosis.
Ann Neurol. 2024 Jul 10. doi: 10.1002/ana.27026. PubMedAbstract available
BRIER MR, Schindler SE, Salter A, Perantie D, et al Unexpected Low Rate of Amyloid-beta Pathology in Multiple Sclerosis Patients.
Ann Neurol. 2024 Jul 4. doi: 10.1002/ana.27027. PubMedAbstract available
GUO A, Zhang Z, Dong GH, Su L, et al Cortical Microhemorrhage Presentation of Small Vessel Primary Angiitis of the
Central Nervous System.
Ann Neurol. 2024;96:194-203. PubMedAbstract available
June 2024
PIEHL F, Alping P, Virtanen S, Englund S, et al COMBAT-MS: A Population-Based Observational Cohort Study Addressing the
Benefit-Risk Balance of Multiple Sclerosis Therapies Compared with Rituximab.
Ann Neurol. 2024 Jun 25. doi: 10.1002/ana.27012. PubMedAbstract available
May 2024
CORTESE R, Battaglini M, Prados F, Gentile G, et al Grey Matter Atrophy and its Relationship with White Matter Lesions in Patients
with Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease, Aquaporin-4
Antibody-Positive Neuromyelitis Optica Spectrum Disorder, and Multiple Sclerosis.
Ann Neurol. 2024 May 23. doi: 10.1002/ana.26951. PubMedAbstract available
GIORDANO A, Pignolet B, Mascia E, Clarelli F, et al DNA Methylation in the Anti-Mullerian Hormone Gene and the Risk of Disease
Activity in Multiple Sclerosis.
Ann Neurol. 2024 May 15. doi: 10.1002/ana.26959. PubMedAbstract available
April 2024
GILLIGAN M, Lesnick CE, Guo Y, Bradshaw MJ, et al Paraneoplastic Calmodulin Kinase-Like Vesicle-Associated Protein (CAMKV)
Autoimmune Encephalitis.
Ann Neurol. 2024 Apr 18. doi: 10.1002/ana.26943. PubMedAbstract available
CALABRESE M, Preziosa P, Scalfari A, Colato E, et al Determinants and Biomarkers of Progression Independent of Relapses in Multiple
Sclerosis.
Ann Neurol. 2024 Apr 3. doi: 10.1002/ana.26913. PubMedAbstract available
March 2024
NEIDHART S, Vlad B, Hilty M, Hogelin KA, et al HLA Associations of Intrathecal IgG Production against Specific Viruses in
Multiple Sclerosis.
Ann Neurol. 2024 Mar 29. doi: 10.1002/ana.26921. PubMedAbstract available
ALPING P, Neovius M, Piehl F, Frisell T, et al Real-World Healthcare Cost Savings and Reduced Relapse Rate with Off-Label
Rituximab versus Disease-Modifying Treatments Approved for Relapsing-Remitting
Multiple Sclerosis: A Nationwide Cost-Effectiveness Study.
Ann Neurol. 2024 Mar 26. doi: 10.1002/ana.26914. PubMedAbstract available
MARGONI M, Pagani E, Meani A, Preziosa P, et al Cognitive Impairment Is Related to Glymphatic System Dysfunction in Pediatric
Multiple Sclerosis.
Ann Neurol. 2024 Mar 13. doi: 10.1002/ana.26911. PubMedAbstract available
February 2024
FADDA G, Yea C, O'Mahony J, Waters P, et al Epstein-Barr Virus Strongly Associates With Pediatric Multiple Sclerosis, But Not
Myelin Oligodendrocyte Glycoprotein-Antibody-Associated Disease.
Ann Neurol. 2024 Feb 27. doi: 10.1002/ana.26890. PubMedAbstract available
SHU Y, Huang R, Li Q, Lu Y, et al Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy Is Associated with
HLA-A*3303 and HLA-DPB1*0501.
Ann Neurol. 2024 Feb 24. doi: 10.1002/ana.26899. PubMedAbstract available
CHOMYK A, Kucinski R, Kim J, Christie E, et al Transcript Profiles of Microglia/Macrophage Cells at the Borders of Chronic
Active and Subpial Gray Matter Lesions in Multiple Sclerosis.
Ann Neurol. 2024 Feb 12. doi: 10.1002/ana.26877. PubMedAbstract available
December 2023
NICHOLAS R, Magliozzi R, Marastoni D, Howell O, et al High levels of perivascular inflammation and active demyelinating lesions at time
of death associated with rapidly progressive multiple sclerosis disease course: a
retrospective post-mortem cohort study.
Ann Neurol. 2023 Dec 27. doi: 10.1002/ana.26870. PubMedAbstract available
MCKAY KA, Wijnands JMA, Manouchehrinia A, Zhu F, et al Risk of Multiple Sclerosis in People Living with HIV: An International Cohort
Study.
Ann Neurol. 2023 Dec 14. doi: 10.1002/ana.26840. PubMedAbstract available
KIM S, Eun MY, Lee JJ, Seok HY, et al Myelin Oligodendrocyte Glycoprotein Antibody-Positive Patients Meeting the 2017
McDonald Criteria for Multiple Sclerosis: Challenges in Diagnosis and Treatment
Decisions.
Ann Neurol. 2023 Dec 12. doi: 10.1002/ana.26859. PubMed
DUCHOW A, Bellmann-Strobl J, Friede T, Aktas O, et al Time to disability milestones and annualized relapse rates in NMOSD and MOGAD.
Ann Neurol. 2023 Dec 12. doi: 10.1002/ana.26858. PubMedAbstract available
VILLACIEROS-ALVAREZ J, Espejo C, Cobo-Calvo A Reply to "Myelin Oligodendrocyte Glycoprotein Antibody-Positive Patients Meeting
the 2017 McDonald Criteria for Multiple Sclerosis: Challenges in Diagnosis and
Treatment Decisions".
Ann Neurol. 2023 Dec 11. doi: 10.1002/ana.26856. PubMed
KNOWLES S, Middleton R, Cooze B, Farkas I, et al Comparing the pathology, clinical and demographic characteristics of younger and
older-onset multiple sclerosis.
Ann Neurol. 2023 Dec 7. doi: 10.1002/ana.26843. PubMedAbstract available
November 2023
KREFT KL, Uzochukwu E, Loveless S, Willis M, et al Relevance of multiple sclerosis severity genotype in predicting disease course: A
real-world cohort.
Ann Neurol. 2023 Nov 17. doi: 10.1002/ana.26831. PubMedAbstract available
October 2023
MAJED M, Valencia Sanchez C, Bennett JL, Fryer J, et al Alterations in Aquaporin-4-IgG Serostatus in 986 Patients: A Laboratory-Based
Longitudinal Analysis.
Ann Neurol. 2023;94:727-735. PubMedAbstract available
September 2023
GASPERI C, Wiltgen T, McGinnis J, Cerri S, et al A genetic risk variant for multiple sclerosis severity is associated with brain
atrophy.
Ann Neurol. 2023 Sep 27. doi: 10.1002/ana.26807. PubMedAbstract available
VILLACIEROS-ALVAREZ J, Espejo C, Arrambide G, Castillo M, et al MOG antibodies in adults with a first demyelinating event suggestive of multiple
sclerosis.
Ann Neurol. 2023 Sep 14. doi: 10.1002/ana.26793. PubMedAbstract available